Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials

• Published in: Advances in therapy Vol. 38; no. 3; pp. 1614 - 1626
• Main Authors: Kuruppu, Dulanji K., North, James M., Kovacik, Amy J., Dong, Yan, Pearlman, Eric M., Hutchinson, Susan L.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.03.2021
• Subjects: Adult; Antibodies, Monoclonal, Humanized; Calcitonin Gene-Related Peptide; Cardiology; Double-Blind Method; Endocrinology; Humans; Internal Medicine; Medicine; Medicine & Public Health; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; Oncology; Original Research; Pharmacology/Toxicology; Randomized Controlled Trials as Topic; Rheumatology; Treatment Outcome; Cessation; Migraine; CGRP antagonist; Galcanezumab; Maintenance; Migraine prevention; Onset

Introduction Galcanezumab, a humanized monoclonal antibody that binds to calcitonin gene-related peptide, is approved for the preventive treatment of migraine in adults. It is self-administered once monthly as a subcutaneous injection. This paper describes the time course of effect of galcanezumab i...